Steroid ointment
AssigneeSchering Corporation
InventorVarda Ecker
Life of this patent
Estimating the term…
Abstract
An improved ointment for the topical administration of steroids is comprised of a therapeutically effective amount of a 17-mono or 17,21-diester of betamethasone in a non-aqueous base comprised of 5-15% of a glycol solvent, 1-3% of a principle emulsifying agent; 0-7% of a secondary emulsifying agent; and 70-90% of a petrolatum base.
Claims18
A method of treating inflammation which comprises applying to the skin a topical formulation comprising an amount effective to treat said inflammation of a dermatologically acceptable anti-inflammatory 17-mono or 17,21-diester of betamethasone in a non-aqueous, water-miscible solvent-in-oil base comprising
- - 15% of a non-aqueous, water-miscible solvent consisting essentially of a glycol solvent selected from the group consisting of
- 1,2-propylenediol, butylene glycol, hexylene glycol and mixtures thereof;
- 1-3% of propylene glycol monostearate;
- 0-7% of white or yellow wax;
- and
- 70-90% of petrolatum.
A topical ointment for the treatment of inflammation which comprises an amount effective to treat said inflammation of a dermatologically acceptable anti-inflammatory 17-mono or 17,21-diester of betamethasone in a non-aqueous, water-miscible solvent-in-oil base comprising
- 5-15% of a non-aqueous, water-miscible solvent consisting essentially of a glycol solvent selected from the group consisting of 1,2-propylenediol, butylene glycol, hexylene glycol and mixtures thereof;
- 1-3% of propylene glycol monostearate;
- 0-7% of white or yellow wax;
- and
- 70-90% of petrolatum.
Dependencies are inferred from the claim text.